A detailed history of Lord, Abbett & Co. LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 702,607 shares of JANX stock, worth $38.2 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
702,607
Previous 542,373 29.54%
Holding current value
$38.2 Million
Previous $20.4 Million 44.13%
% of portfolio
0.1%
Previous 0.07%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Oct 07, 2024

BUY
$35.12 - $64.78 $5.63 Million - $10.4 Million
160,234 Added 29.54%
702,607 $29.4 Million
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $5.63 Million - $10.4 Million
160,234 Added 29.54%
702,607 $29.4 Million
Q1 2024

Oct 07, 2024

SELL
$7.93 - $49.75 $1.27 Million - $7.97 Million
-160,234 Reduced 22.81%
542,373 $20.4 Million
Q1 2024

May 09, 2024

BUY
$7.93 - $49.75 $4.3 Million - $27 Million
542,373 New
542,373 $20.4 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.27B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Lord, Abbett & Co. LLC Portfolio

Follow Lord, Abbett & Co. LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.